These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Savings achieved through cephalosporin surveillance. Katz E; Schlamowitz S Am J Hosp Pharm; 1978 Dec; 35(12):1521-3. PubMed ID: 717407 [TBL] [Abstract][Full Text] [Related]
6. The effect of an education program on cefazolin prescribing. Blain L; O'Brodovich M Can J Hosp Pharm; 1989 Apr; 42(2):69-71. PubMed ID: 10292923 [TBL] [Abstract][Full Text] [Related]
7. Drug usage review and inventory analysis in promoting rational parenteral cephalosporin therapy. Simon WA; Thompson L; Campbell S; Lantos RL Am J Hosp Pharm; 1975 Nov; 32(11):1116-21. PubMed ID: 1190230 [TBL] [Abstract][Full Text] [Related]
8. Impact of parenteral cephalosporin regulation on pharmacy costs. Ryan JL; Francese J Hosp Formul; 1983 May; 18(5):510-2. PubMed ID: 10260198 [No Abstract] [Full Text] [Related]
9. Impact of education on cephalosporin prescribing patterns. Frye CB; Baker B; Sexton DJ; Dougherty FK J Okla State Med Assoc; 1987 Sep; 80(9):649-53. PubMed ID: 3668708 [No Abstract] [Full Text] [Related]
11. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Woodward RS; Medoff G; Smith MD; Gray JL Am J Med; 1987 Nov; 83(5):817-23. PubMed ID: 3674089 [TBL] [Abstract][Full Text] [Related]
12. Controlling moxalactam and cefotaxime use with a target drug program. Abramowitz PW; Ludwig DJ; Mansur JM; Nold EG Hosp Pharm; 1983 Aug; 18(8):416-20. PubMed ID: 10261791 [TBL] [Abstract][Full Text] [Related]
13. Financial impact of formulary revision of second-generation cephalosporins. Andrews JD; Hafting S Can J Hosp Pharm; 1988 Jun; 41(3):125-7. PubMed ID: 10288499 [TBL] [Abstract][Full Text] [Related]
14. Cost containment through restriction of cephalosporins. Britton HL; Schwinghammer TL; Romano MJ Am J Hosp Pharm; 1981 Dec; 38(12):1897-900. PubMed ID: 7325168 [TBL] [Abstract][Full Text] [Related]
15. Use of benchmarking techniques to justify the evolution of antibiotic management programs in healthcare systems. Schentag JJ; Paladino JA; Birmingham MC; Zimmer G; Carr JR; Hanson SC J Pharm Technol; 1995; 11(5):203-10. PubMed ID: 10151512 [TBL] [Abstract][Full Text] [Related]
16. Use of staff pharmacists to reduce the inappropriate use of parenteral histamine-2 antagonist therapy. Caldwell RD; Davis SK Hosp Pharm; 1987 Dec; 22(12):1205-9. PubMed ID: 10285375 [TBL] [Abstract][Full Text] [Related]
17. Is there cost reduction potential for extended half-life cephalosporins? Scalley RD; Stuart CC Drug Intell Clin Pharm; 1986 Dec; 20(12):975-80. PubMed ID: 3816548 [TBL] [Abstract][Full Text] [Related]